— Technology Description
Researchers from Washington University in St. Louis and colleagues have identified ent-allopregnanolone (ent-AlloP) as a potential therapeutic to treat glaucoma. Glaucoma, the leading cause of irreversible blindness, results from damage to the retinal ganglion cells (RGSs) t…
— Technology Description
Researchers at Washington University in St. Louis have developed a vaccine strategy to prevent catheter-associated urinary tract infections (CAUTIs). CAUTIs are the most common cause of hospital-acquired infections. Many of these are caused by Enterococcus bacteria. CAUTIs a…
— Technology Description
Researchers in Prof. Jeffrey Henderson’s laboratory have discovered a drug target and a class of small molecule candidates that could be used to selectively prevent pathogenic enterobacteria from causing diseases such as urinary tract infections (UTIs).
Currently, UTI…
— Disease indication – Tetracycline resistant infections
Drug format – Small molecule (anhydrotetracycline (aTC) or analogs)
Drug class – Combination therapy
Research stage and Preliminary data
Target – Tetracycline destructases (Tet(X), Tet(50), etc)
Background &ndas…
— Technology Description
Researchers in Prof. Rajendra Apte’s laboratory developed novel methods for treating macular degeneration and other eye diseases by targeting a cholesterol transport pathway involved in the formation of new blood vessels. Age-related macular degeneration (AMD) is a lea…
| Name | # Summaries | Author | Action |
|---|---|---|---|
| 15 | |||
| 13 | |||
| 1 | |||
| 15 | |||
| 26 | |||
| 14 | |||
| 14 |
Creating...
